Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for Leukemia therapy

Cancer Research

Volumn 75, Issue 23, 2015, Pages 5106-5119

  Picaud, Sarah ^a   Fedorov, Oleg ^a   Thanasopoulou, Angeliki ^b   Leonards, Katharina ^b   Jones, Katherine ^c   Meier, Julia ^a   Olzscha, Heidi ^d   Monteiro, Octovia ^a   Martin, Sarah ^a   Philpott, Martin ^a   Tumber, Anthony ^a   Filippakopoulos, Panagis ^a   Yapp, Clarence ^a   Wells, Christopher ^a   Che, Ka Hing ^e   Bannister, Andrew ^e   Robson, Samuel ^e   Kumar, Umesh ^c   Parr, Nigel ^c   Lee, Kevin ^c   Lugo, Dave ^c   Jeffrey, Philip ^c   Taylor, Simon ^c   Vecellio, Matteo L ^a   Bountra, Chas ^a   Brennan, Paul E ^a   O'Mahony, Alison ^f   Velichko, Sharlene ^f   Muller, Susanne ^a   Hay, Duncan ^a   Daniels, Danette L ^g   Urh, Marjeta ^g   La Thangue, Nicholas B ^d   Kouzarides, Tony ^e   Prinjha, Rab ^c   Schwaller, Jurg ^b   Knapp, Stefan ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f DiscoveRx Corporation   (United States)

^g PROMEGA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY N (1,2,3,4 TETRAHYDRO 3 METHYL 2 OXO 6 QUINAZOLINYL)BENZENESULFONAMIDE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; ACYLTRANSFERASE INHIBITOR; ANTILEUKEMIC AGENT; DOXORUBICIN; HISTONE ACETYLTRANSFERASE PCAF; I CBP 112; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; OXAZEPINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL GROWTH; CELL RENEWAL; CHROMOSOME TRANSLOCATION; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; ENZYMOLOGY; LEUKEMIA, MYELOID, ACUTE; MOLECULAR GENETICS; MOLECULAR MODEL; MOUSE; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXAZEPINES; P300-CBP TRANSCRIPTION FACTORS; PROTEIN STRUCTURE, TERTIARY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955511303     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0236     Document Type: Article

References (50)

1. Chen J, Li Q. Life and death of transcriptional co-activator p300. Epigenetics 2011;6:957-61.
2. Delvecchio M, Gaucher J, Aguilar-Gurrieri C, Ortega E, Panne D. Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation. Nat Struct Mol Biol 2013;20: 1040-6.
3. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM, et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000;14:272-7.
4. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998;93:361-72.
5. Chan WI, Hannah RL, Dawson MA, Pridans C, Foster D, Joshi A, et al. The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells. Mol Cell Biol 2011;31:5046-60.
6. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23: 4225-31.
7. Katsumoto T, Yoshida N, Kitabayashi I. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci 2008;99:1523-7.
8. Zhang Y, Zeleznik-Le N, Emmanuel N, Jayathilaka N, Chen J, Strissel P, et al. Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16). Genes Chromosomes Cancer 2004;41: 257-65.
9. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997;90:535-41.
10. Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol 1999;19:764-76.
11. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006;26:2782-90.
12. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011;333:765-9.
13. Arif M, Pradhan SK, Thanuja GR, Vedamurthy BM, Agrawal S, Dasgupta D, et al. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J Med Chem 2009;52:267-77.
14. Santer FR, Hoschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 2011;10:1644-55.
15. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, et al. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One 2013;8: e55481.
16. Borah JC, Mujtaba S, Karakikes I, Zeng L, Muller M, Patel J, et al. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol 2011;18:531-41.
17. Hewings DS, Wang M, Philpott M, Fedorov O, Uttarkar S, Filippakopoulos P, et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 2011;54:6761-70.
18. Vidler LR, Brown N, Knapp S, Hoelder S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem 2012;55:7346-59.
19. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
20. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010;468:1119-23.
21. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res 2013;73:3336-46.
22. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
23. Fedorov O, Niesen FH, Knapp S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol Biol 2012;795: 109-18.
24. Philpott M, Yang J, Tumber T, Fedorov O, Uttarkar S, Filippakopoulos P, et al. Bromodomain-peptidedisplacement assays forinteractome mapping and inhibitor discovery. Mol Biosyst 2011;7:2899-908.
25. Filippakopoulos P, Picaud S, Fedorov O, Keller M, Wrobel M, Morgenstern O, et al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem 2012;20:1878-86.
26. Philpott M, Rogers CM, Yapp C, Wells C, Lambert JP, Strain-Damerell C, et al. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. Epigenetics Chromatin 2014;7:14.
27. Ciceri P, Muller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, et al. Dual kinase-bromodomain inhibitors for rationally designed poly-pharmacology. Nat Chem Biol 2014;10:305-12.
28. Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 2014;136:9308-19.
29. Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 2000;19:4655-64.
30. Mereau H, DeRijck J, Cermakova K, Kutz A, Juge S, Demeulemeester J, et al. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Leukemia 2013;27:1245-53.
31. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.
32. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J 2010;29: 2943-52.
33. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
34. Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, et al. Differential gene expression of activating Fcgamma receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 2014;20:O230-8.
35. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-11.
36. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014;13:337-56.
37. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
38. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell 2014;54:728-36.
39. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
40. Bolden JE, Tasdemir N, Dow LE, van Es JH, Wilkinson JE, Zhao Z, et al. Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Cell Rep 2014;8:1919-29.
41. Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI, Kung AL. Systematic in vivo structure-function analysis of p300 in hematopoiesis. Blood 2009;114:4804-12.
42. Kang-Decker N, Tong C, Boussouar F, Baker DJ, Xu W, Leontovich AA, et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell 2004;5:177-89.
43. Xu W, Fukuyama T, Ney PA, Wang D, Rehg J, Boyd K, et al. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. Blood 2006;107:4407-16.
44. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P, et al. Conditional MLL-CBP targets GMP and models therapy-related myelo-proliferative disease. EMBO J 2005;24:368-81.
45. Pattabiraman DR, McGirr C, Shakhbazov K, Barbier V, Krishnan K, Mukhopadhyay P, et al. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood 2014;123:2682-90.
46. Mendonca DB, Mendonca G, Cooper LF. Mammalian two-hybrid assays for studies of interaction of p300 with transcription factors. Methods Mol Biol 2013;977:323-38.
47. Wei L, Jamonnak N, Choy J, Wang Z, Zheng W. Differential binding modes of the bromodomains of CREB-binding protein (CBP) and p300 with acetylated Myo D. Biochem Biophys Res Commun 2008;368: 279-84.
48. Hou T, Ray S, Lee C, Brasier AR. The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem 2008;283:30725-34.
49. Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand, et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004;13:251-63.
50. Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A 2014;111:E2721-30.